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Objectives The goal of this research was to identify disparities in risk within heart transplant urgency designations.
Background Patients with left ventricular assist devices (LVADs) are given 30 days of elective status 1A time. This allowance may create
competition for organs between stable LVAD-supported registrants and less stable registrants listed status 1A or 1B.
Methods The Scientific Registry of Transplant Recipients database was analyzed for all status 1A and 1B listings between
2005 and 2010. Cox models were used to estimate the relative and absolute risk of adverse events (death or
delisting as too ill) during status 1A or 1B listing.
Results Status 1A registrants supported with dual inotropes and right heart monitoring had a higher risk of adverse
events compared to those supported with implanted LVADs using elective 1A time (hazard ratio: 3.2; 95%
confidence interval: 1.8 to 5.7). The 30-day risk of events was 1% (95% confidence interval: 0.1% to 3%) for im-
planted LVADs using elective 1A time and 6% (95% confidence interval: 4% to 8%) for dual inotrope support.
Registrants listed with paracorporeal ventricular assist devices had a higher risk of adverse events (hazard ratio:
9.1; p  0.0001) compared with registrants with implanted LVADs using elective 1A time. The odds of trans-
plant were higher for implanted LVADs (odds ratio: 1.5; p  0.0001) compared with dual-inotrope and intra-
aortic balloon pump support.
Conclusions The historic allowance for 30 days of elective status 1A time for implanted LVADs creates disparities in risk among
status 1A registrants. The allowance of 30 days of elective status 1A time should not be allocated to stable regis-
trants with implanted LVADs. Registrants supported with paracorporeal ventricular assist devices should be listed sta-
tus 1A indefinitely. (J Am Coll Cardiol 2012;60:36–43) © 2012 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.031Early in the course of ventricular assist device (VAD)
development, 30 days of Organ Procurement and Trans-
plantation Network (OPTN) status 1A time was given to
patients immediately after VAD placement to allow for
recovery from VAD surgery before transplant listing. This
policy was later changed in 2002 to allow 30 days of status
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supported registrants to use elective 1A time (1). Patients
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30 days of elective 1A time are listed status 1B.
Survival has steadily improved for patients supported with
implanted left ventricular assist devices (LVADs) as expe-
rience with LVAD placement and long-term management
increases and devices become more reliable (2,3). The
30-day allowance still exists but may allow competition
between patients with very different risks of death. Stable
registrants with implanted LVADs are likely to have a much
lower risk of death than other patients listed status 1A (4).
Because LVADs are used more commonly, there is a
growing belief that placement of an LVAD is necessary for
successful transplantation. Increasing numbers of stable,
VAD-supported patients listed status 1A may prevent organ
allocation to sicker patients, decreasing survival among those
waiting for transplant and leading to an overall reduction in
the efficacy of the transplant urgency system.
We assessed the equality of risk among registrants listed
status 1A and 1B who were actively listed for transplant and
demonstrate significant disparities in risk within and be-
tween OPTN status designations.
Methods
This study used data from the Scientific Registry of Transplant
Recipients (SRTR). The SRTR data system includes data on
all donor, wait-listed candidates, and transplant recipients in
the United States submitted by a member of the OPTN; this
system has been described elsewhere. The Health Resources
and Services Administration, U.S. Department of Health and
Human Services, provides oversight to the activities of the
OPTN and SRTR contractors. Subjects with complete listing
dates, listing status justification, initial listing and list removal
dates, VAD type, VAD implantation dates, and, for transplant
recipients, transplant date and date of death or graft failure
were included. The current analysis focused on January 2005 to
November 2010 to obtain accurate information on modern
implanted and paracorporeal VADs.
For status 1A registrants, status justifications were recorded
by OPTN as either VAD support using elective time, VAD
support with a complication, ventilator dependence, inotropic
support and/or intra-aortic balloon pump support (referred to
hereafter as “medical support”), and exception status. We
further separated registrants justified as “VAD support using
elective time” into those with an implanted LVAD and those
with a paracorporeal device to create 6 subgroups for analysis.
Those with an implanted LVAD and simultaneous paracor-
poreal right-sided VAD were assigned to the paracorporeal
support group. Total artificial hearts were excluded from the
analysis. For status 1B registrants, status justifications included
low-dose single inotrope, implanted LVADs, paracorporeal
devices that were defined similarly to status 1A registrants, and
all others not meeting those criteria, which include those listed
status 1B with exception.
Demographic characteristics are reported according to
transplant urgency status and status justification code present atthe time of initial listing. Trends
over time in status 1A and 1B
listing justifications were analyzed
by year using the Poisson regres-
sion or Cochran-Armitage test for
trend. Time to listing after VAD
placement surgery was calculated
from the VAD placement date
until the next status 1A or 1B
listing. Median listing refers to the
time from initial listing until re-
moval from that listing status for
any reason (i.e., transplant, death).
We assessed the frequency of sta-
tus 1A listing of stable, implanted
LVAD registrants simultaneous to
other types of status 1A candidates
within transplanting centers and
within organ procurement organiza-
tions (OPO). Listing was only considered to be simultaneous
when a registrant with an implanted LVAD using status 1A
elective time was listed at the same time as another registrant listed
status 1A with the same blood type.
The composite endpoint was defined as death while on
the waiting list or delisting as too ill for transplant. Two
separate types of Cox hazard model analysis were performed
to measure risk on the basis of the following: 1) active status
designation and status justification (in-status analysis),
which only counts a registrant at-risk when listed in a
specific status and justification (i.e., time at-risk is only
measured while listed status 1A and justified by a VAD with
a complication); and 2) risk after first status designation and
justification (first-status analysis), which includes all time
after initial listing regardless of subsequent status or justifi-
cation after initial listing (i.e., time at-risk begins with the
first listing date, status, and justification and ends at the
time of an event or censoring regardless of subsequent status
or justification changes). The in-status analysis is useful to
compare risk among registrants in the same status, whereas
the first-status analysis allows assessment of risk after the
initial presentation and includes all time on the list regard-
less of events after the first listing. Models were stratified
according to status justification to measure the cumula-
tive hazard. Hazard ratios (HRs) were obtained using
dummy variable coding and were adjusted for age, sex,
ABO blood type, and heart failure etiology. The counting
method was used to compile the time at-risk to adjust for
discontinuous listing episodes and changes in status
justification over time. Registrants were censored as free
of the composite endpoint at the time of transplant or if
the composite outcome had not occurred before Novem-
ber 10, 2010. We also measured the cumulative hazard
and relative hazard of death 30 days before and after
VAD implantation to separate acute VAD support from
Abbreviations
and Acronyms
CI  confidence interval
HR  hazard ratio
IQR  interquartile range
LVAD  left ventricular
assist device
OPO  organ procurement
organization
OPTN  Organ
Procurement and
Transplantation Network
OR  odds ratio
SRTR  Scientific Registry
of Transplant Recipients
VAD  ventricular assist
devicelong-term support.
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sion models adjusted for age, etiology of heart failure, ABO
blood type, sex, and status justification for status 1A and
status 1B registrants.
Mortality after transplant was calculated with standard
Cox models stratified by transplant status and status justi-
fication. Mortality was adjusted for age.
All analyses were conducted by using SAS version 9.2
(SAS Institute Inc., Cary, North Carolina).
Results
Sample characteristics. The sample included 11,908 status
1A listings with 267 events for the in-status analysis and
7,064 individuals with 1,073 events for the first-status
analysis (Table 1). There were 13,260 status 1B listings with
972 events for the in-status analysis and 8,368 individuals
with 1,135 events for the first-status analysis. The type of
VAD placed changed from pulsatile devices to continuous
flow devices over the course of the study. The most common
device placed in 2005 was the HeartMate XVE (Thoratec,
Demographic Characteristics According to OPTN Status and StatusTable 1 Demographic Characteristics According to OPTN Statu
Characteristic
Status 1A
Paracorporeal
Implanted
LVAD
VAD With
Complication Ventilator
Age (yrs) 46 16 46 17 46 17 47 15
Sex (% male) 80 77 79 80
Race (%)
White 83 82 85 8
African American 11 16 8 12
Other 6 2 7 80
BMI (kg/m2) 25 6 25 6 25 7 25 5
Individuals 1,628 1,086 330 232
Listings 1,877 2,289 1,505 323
Events 355 75 55 75
Values are mean  SD, %, or n.
BMI  body mass index; LVAD  left ventricular assist device; OPTN  Organ Procurement and
Unadjusted and Adjusted HRs While ListedTable 2 Unadjusted and Adjusted HRs While
Patient Status
Unadju
HR 95% C
Status 1A
Implanted LVAD elective time Ref
Paracorporeal 9.10 5.2–16
VAD with complication 1.80 0.9–3.
Ventilator 14.20 7.4–27
Medical† 3.20 1.8–5.
Exception 6.60 3.4–13
Status 1B
Implanted LVAD Ref
Medical† 2.20 1.7–2.
Paracorporeal 4.20 2.9–6.
Exception/other 2.50 1.8–3.
*Adjusted for age, ABO blood type, sex, and heart failure etiology (
inotrope  intra-aortic balloon pump support for status 1A and single, low
CI  confidence interval; HR  hazard ratio; Ref  reference group; otherPleasanton, California) (55%). By 2010, 75% of devices
placed were the HeartMate II (Thoratec).
Adverse events while waiting for transplant. Compared
with elective status 1A registrants listed with an implanted
LVAD, registrants with a VAD and a complication had a
risk of adverse events that was not significantly higher (HR:
1.8; 95% confidence interval [CI]: 0.90 to 3.5), whereas
those with paracorporeal VADs (HR: 9.1; 95% CI: 5.2 to
16) and those with medical support (HR: 3.2; 95% CI: 1.8
to 5.7) had a significantly higher risk of events (Table 2,
Fig. 1), as analyzed according to the in-status analysis.
These associations did not change after adjusting for age,
ABO blood type, sex, and etiology of heart failure (Table 2).
The first-status analysis, allowing for subsequent status
changes and periods of delisting or hold status, were not
appreciably different with respect to the relative risk of
adverse events between status 1A justifications, while tend-
ing to increase the rate of adverse events for all groups
(Table 3, Fig. 2). The cumulative hazard within 30 days of
status elective 1A listing for an implanted LVAD was 1.0%
ificationd Status Justification
Status 1B
ical Exception Medical Paracorporeal
Implanted
LVAD Exception/Other
16 46 16 51 13 52 11 48 14 51 13
79 76 75 73 79 76
83 82 67 72 67 78
11 11 22 16 24 12
6 7 11 12 9 10
6 25 7 27 9 28 20 29 5 28 5
34 454 6,967 221 685 495
18 696 10,276 334 1,603 1,047
42 71 934 45 81 75
plantation Network; VAD  ventricular assist device.
ed
Adjusted*
p Value HR 95% CI p Value
Ref
0.0001 8.50 4.8–15 0.0001
0.10 1.70 0.8–3.3 0.14
0.0001 13.00 7.0–26.0 0.0001
0.0001 2.90 1.6–5.3 0.0003
0.0001 5.40 2.8–11 0.0001
Ref
0.0001 2.10 1.7–2.6 0.0001
0.0001 4.10 2.9–6.0 0.0001
0.0001 2.40 1.7–3.2 0.0001
ic, nonischemic, and congenital). †Dual-inotrope, single high-doseJusts an
Med
47
25
3,3
5,2
4List
sted
I
5
.0
7
7
0
4
ischem
-dose inotrope for status 1B.
abbreviations as in Table 1.
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July 3, 2012:36–43 LVADs and Risk While Awaiting Heart Transplant(95% CI: 0.05% to 3%), VAD with complication was 6%
(95% CI: 3% to 14%), medical therapy was 6% (95% CI: 4%
to 8%), and 1A paracorporeal VAD was 15% (95% CI: 12%
to 20%) (Table 3). Biventricular support with either im-
planted or paracorporeal devices (HR: 2.1; 95% CI: 0.64 to
Figure 1 Cumulative Event Rate for
Status 1A In-Status Model
Registrants are only at-risk when in a selected justification status. Events are
defined as death or delisting as too ill. Elective  30 days elective time;
IABP  intra-aortic balloon pump; LVAD  left ventricular assist device;
VAD  ventricular assist device.
Cumulative Hazard of Adverse Events WhileListed In-Status and in Any Status After Initial LTable 3 Cumulat ve Hazard of Adv se EvenListed In-Status and in Any Status A
Patient Status 30-Day
While listed in specified status
Status 1A
Implanted LVAD 0.01
VAD with complication 0.06
Medical* 0.06
Exception 0.06
Paracorporeal VAD 0.15
Ventilator 0.30
Status 1B
Implanted LVAD 0.03
Medical* 0.09
Exception 0.13
Paracorporeal 0.26
From first appearance to list removal
Status 1A
Implanted LVAD 0.02
VAD with complication 0.09
Medical* 0.09
Exception 0.11
Paracorporeal VAD 0.17
Ventilator 0.26
Status 1B
Implanted LVAD 0.02
Medical* 0.05
Exception 0.06
Paracorporeal 0.10*Dual-inotrope, single high-dose inotrope  intra-aortic balloon pump suppor
Abbreviations as in Table 2.6.8) or right-sided VAD (HR: 2.3; 95% CI: 0.2 to 21) was
associated with a higher risk of mortality that was not
statistically different from implanted LVAD support, al-
though insufficient numbers of patients had complete VAD
support information to adequately assess the differences
between implanted and paracorporeal support.
We assessed the relative hazard of adverse events within
groups of patients supported with a VAD relative to the
time from VAD surgery to their first status 1A designation.
Adverse events occurred more commonly among those with
paracorporeal devices when the registrant was listed 30
ays after VAD implantation (HR: 8.6; 95% CI HR: 2.1 to
6) and was 4.9 times higher (95% CI HR: 1.7 to 14) for
hose with implanted devices.
Status 1B registrants with medical support (HR: 2.2; 95%
I: 1.7 to 2.7), paracorporeal VADs (HR: 4.2; 95% CI: 2.9
o 6.0), and those listed 1B with exception (HR: 2.5; 95%
I: 1.8 to 3.4) all had a higher risk of adverse events
ompared with status 1B registrants listed with implanted
ADs according to the in-status analysis (Table 2, Fig. 3).
These trends did not change after adjusting for age, ABO
blood type, sex, and etiology of heart failure; they also did
not change in the first-status analysis (Table 3, Fig. 4). The
cumulative hazard at 30 days after initial listing for implanted
VADs was 3% (95% CI: 2% to 4%), single inotrope support
hile
Initial Listing
95% CI 90-Day 95% CI
0.005–0.03 0.03 0.01–0.06
0.03–0.14 0.10 0.05–0.19
0.04–0.08 0.10 0.07–0.14
0.03–0.14 0.25 0.14–0.44
0.12–0.20 0.25 0.19–0.33
0.19–0.47 0.44 0.27–0.71
0.02–0.04 0.06 0.04–0.08
0.08–0.10 0.17 0.16–0.19
0.08–0.20 0.29 0.22–0.39
0.18–0.39 0.36 0.25–0.51
0.01–0.03 0.07 0.05–0.10
0.06–0.13 0.21 0.15–0.29
0.08–0.10 0.18 0.16–0.21
0.08–0.15 0.28 0.20–0.38
0.15–0.20 0.32 0.29–0.37
0.20–0.36 0.38 0.29–0.52
0.01–0.03 0.04 0.03–0.07
0.04–0.06 0.12 0.11–0.13
0.04–0.09 0.15 0.11–0.20
0.07–0.16 0.22 0.15–0.32istingt W
ftert for status 1A and single, low-dose inotrope for status 1B.
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support was 26% (95% CI: 18% to 39%) (Table 3).
For status 1B registrants with VADs, the risk of adverse
events among those with an implanted VAD (HR: 1.6; 95%
CI: 0.98 to 2.5) or a paracorporeal VAD (HR: 2.0; 95% CI:
3.7 to 1.02) was higher when the registrant was listed within
30 days of implantation compared with those listed for
transplant 30 days after implantation.
Status 1A listing trends. Of all status 1A listings between
2005 and 2010, candidates listed status 1A with an im-
planted LVAD without complication increased from 11%
to 26% (p  0.0001), VADs with complications increased
from 11% to 13% (p  0.0001), paracorporeal devices
ecreased from 25% to 14% (p 0.03), and medical support
ecreased from 44% to 39% (p  0.0001) (Fig. 5).
The median length of a single listing episode for im-
lanted LVADs without complication was 17 days (inter-
Figure 2 Cumulative Event Rate for
Status 1A First-Status Analysis
Registrants are characterized according to status at first appearance on the
list, and the at-risk time contains all status transitions until an event (death or
delisting as too ill) occurs, regardless of subsequent status changes. Abbrevia-
tions as in Figure 1.
Figure 3 Cumulative Event Rate for
Status 1B In-Status Model
Registrants are only at-risk when in a selected justification status.
Events are defined as death or delisting as too ill. Abbreviations as in Figure 1.cuartile range [IQR]: 6 to 30 days), VADs with complica-
ion was 19 days (IQR: 9 to 42 days), paracorporeal VADs
as 6 days (IQR: 2 to 17 days), and medical support was 6
ays (IQR: 3 to 12 days).
Patients with implanted VADs using elective status 1A
ime simultaneously with patients in other status justifica-
ions occurred 105 times at the center level and 119 times at
he OPO level between 2005 and 2010. There were 2
enters with 5 simultaneous listings and 33 OPOs with
10 simultaneous listings.
tatus 1B listing trends. The sample included 10,279 status
B registrants with 17,295 listing episodes. Of all listings from
005 to 2010, support with a single low-dose inotrope decreased
rom 82% to 70% (p 0.0001), implanted VADs increased from
% to 21% (p  0.0001), and paracorporeal VADs decreased
rom 4% to 2% (p  0.0001).
The median length of a single listing episode for im-
lanted LVADs was 41 days (IQR: 11 to 114 days),
aracorporeal VADs was 17.5 days (IQR: 5 to 42 days), and
ow-dose inotrope was 14 days (IQR: 3 to 49 days).
actors influencing likelihood of transplant. The likeli-
ood of transplantation for a patient supported with an
mplanted LVAD using status 1A elective time increased
ver the course of observation from 11% to 27% of all status
A transplants performed. The likelihood of transplantation
ecreased for those with medical support (38% to 35%) and
or those with paracorporeal support (27% to 14%). These
rends in allocation are consistent with the frequency of
isting for each subgroup (Fig. 5).
Among status 1A registrants, implanted LVADs without
omplications (odds ratio [OR]: 1.5; 95% CI: 1.3 to 1.6),
aracorporeal VADs (OR: 1.3; 95% CI: 1.2 to 1.5), and
ADs with a complication (OR: 1.9; 95% CI: 1.7 to 2.2)
ere all more likely to undergo transplantation than medi-
Figure 4 Cumulative Event Rate for
Status 1B First-Status Analysis
Registrants are characterized according to status at first appearance on the
list, and the at-risk time contains all status transitions until an event (death or
delisting as too ill) occurs, regardless of subsequent status changes. Abbrevia-
tions as in Figure 1.ally supported registrants. Women were less likely to be
(
1
(
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July 3, 2012:36–43 LVADs and Risk While Awaiting Heart Transplanttransplanted than men (OR: 0.88; 95% CI: 0.81 to 0.97).
Blood type A (OR: 1.6; 95% CI: 1.5 to 1.7), type B (OR:
1.5; 95% CI: 1.4 to 1.7), and type AB (OR: 2.5; 95% CI: 2.0
to 3.2) registrants had an advantage over type O registrants
for receipt of transplant.
Among status 1B registrants, non-VAD supported reg-
istrants were less likely to undergo transplantation than
those with implanted LVADs (OR: 0.52; 95% CI: 0.47 to
0.57) or those with paracorporeal VADs (OR: 0.79; 95%
CI: 0.64 to 0.97). Women were less likely to be transplanted
than men (OR: 0.82; 95% CI: 0.8 to 0.9). Blood type A
(OR: 1.7; 95% CI: 1.5 to 1.8), type AB (OR: 2.4; 95% CI:
2.0 to 2.9), and type B (OR: 1.5; 95% CI: 1.4 to 1.6)
registrants had an advantage relative to type O registrants
for receipt of transplant.
Post-transplant mortality according to status justification.
After status 1A transplantation, ventilator-dependent (HR:
2.6; 95% CI: 1.7 to 4.1) registrants had a significantly higher
risk of death post-transplant compared with those with
medical support, whereas those with an implanted LVAD
(HR: 1.2; 95% CI: 0.9 to 1.3), those listed as exception
(HR: 1.2; 95% CI: 0.9 to 1.6), paracorporeal VADs (HR:
1.3; 95% CI: 1.0 to 1.5), and VADs with complications
(HR: 1.2; 95% CI: 1.0 to 1.4) all had similar outcomes after
transplant (Table 4, Fig. 6).
After 1B transplant, those with paracorporeal VADs
HR: 1.3; 95% CI: 1.0 to 1.8), implanted LVADs (HR:
.1; 95% CI: 0.9 to 1.3), and those listed with exception
Figure 5 Trends in Status Justifications for OPTN Status 1A Lis
OPTN  Organ Procurement and Transplantation Network; other abbreviations asHR: 1.2; 95% CI: 1.0 to 1.5) had no worse prognosisthan those supported with low-dose inotropes before
transplant (Table 4).
Discussion
The OPTN heart transplant urgency system allows 30 days
of elective status 1A time for LVAD patients. Historically,
this option allowed patients to recover from LVAD place-
ment before using status 1A time. On the basis of our
analysis, allowing elective status 1A time for implanted
LVAD patients creates a disparity in what should be equal
risk among status 1A registrants.
The use of implanted LVADs as a bridge to transplant is
a well-established strategy that allows patients to be stabi-
re 1.
Post-Transplant Mortality Adjusted for AgeTable 4 Post-Transplant Mortality Adjusted for Age
Patient Status HR 95% CI p Value
Status 1A (reference medical*)
Paracorporeal VAD 1.30 0.9–1.8 0.110
Implanted LVAD 1.20 0.88–1.3 0.440
VAD with complication 1.20 0.99–1.4 0.070
Ventilator 2.63 1.7–4.1 0.0001
Exception 1.19 0.9–1.6 0.190
Status 1B (reference medical*)
Paracorporeal 1.30 0.99–1.8 0.099
Implanted LVAD 1.08 0.9–1.3 0.442
Exception/other 1.20 1.0–1.5 0.066
*Dual-inotrope, single high-dose inotrope  intra-aortic balloon pump support for status 1A andting
in Figusingle, low-dose inotrope for status 1B.
Abbreviations as in Table 2.
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for transplant surgery or long-term destination therapy
(3,5–7). However, compared with registrants with dual-
inotrope and intra-aortic balloon pump support, exception
status, or VADs with complications, those using elective
time with an implanted LVAD have a much lower risk of
adverse events. Our study demonstrates that the stability
achieved with implanted LVADs is much greater than can
be achieved among other subgroups of patients listed status
1A. Implanted LVAD registrants have the advantage of
waiting in status 1B for longer periods of time in a relatively
stable clinical condition and the option of status 1A listing
for 30 days. Implanted LVAD registrants can be escalated
to status 1A for device complications, allosensitization, or
other exception criteria. Their clinical stability and unique
listing options result in a higher likelihood of transplant that
is not proportional to their low risk of adverse events relative
to other registrants listed status 1A.
Registrants with paracorporeal support have the highest
risk of adverse events while awaiting transplant. Both
patients with implanted LVADs and those with paracorpo-
real devices share the ability to receive 30 days of elective
status 1A time, while clearly not sharing the same risk of
adverse events. The absolute difference between paracorpo-
real VAD support and implanted LVADs was 14% at 30
days and 22% at 90 days. Registrants with paracorporeal
devices who have used their 30 days of elective time remain
high-risk when listed status 1B. The difference between im-
planted LVAD support and paracorporeal support, regardless
of 1A or 1B status, is certainly enough to warrant a careful
examination of OPTN policy. Registrants with paracorporeal
device support may warrant indefinite 1A status.
Post-transplant survival after LVAD support is not superior
to medical therapy or any other status 1A justification. As such,
there is no compelling reason from the standpoint of organ
utility to favor the transplant of VAD-supported registrants.
Figure 6 Cumulative Mortality After Transplantation
According to Pre-Transplant Status 1A Justification
Registrants are followed up from the time of transplant until death.
Abbreviations as in Figure 1.Only registrants justified with ventilator support had markedlyworse post-transplant outcomes. This group also had markedly
higher risk of events while awaiting transplant.
There are significant differences in risk between status 1B
registrants with implanted LVADs, paracorporeal VADs,
and those supported with single, low-dose inotropes. The
difference between implanted LVADs and medical support
was 6% at 30 days and 11% at 90 days. The difference
between inotrope-supported status 1B registrants and para-
corporeal VADs listed status 1B was 15% at 30 days and
19% at 90 days, suggesting that patients supported with
paracorporeal VADs who remain transplant candidates
should remain listed status 1A indefinitely. The very low
risk of adverse events among both status 1A and 1B subjects
with implanted LVADs suggests that these registrants may
warrant an urgency listing between status 1B and status 2.
Transplant listing and organ allocation. Registrants with
an implanted LVAD have significantly higher rates of
transplantation (OR: 1.5; p  0.0001) compared with those
with dual-inotrope and intra-aortic balloon pump support
registrants, even after adjusting for factors commonly asso-
ciated with the likelihood of organ allocation. We identified
few instances in which a listing center created competition
between those with an implanted LVAD using elective time
and other groups of status 1A registrants. Few additional
instances of apparent mismatch were seen when expanding
the level of analysis to the OPO level. These findings
suggest that transplant centers rarely create internal compe-
tition between stable LVAD-supported registrants and
more high-risk registrants. Between-center competition is
also rarely generated among groups of disparate risk, as
measured by conflicts at the OPO level. However, there
may be important exceptions within certain regions where
the transplant center density is high and between regions
where boundaries create competition for organ allocation.
Allowing continued elective use of status 1A time for
implanted LVAD registrants, although unlikely to result in
a meaningful number of major disparities, is associated with
an inequity in organ provision. Registrants not supported
with LVADs are at higher risk of adverse events. In the
absence of changes to OPTN policy concerning LVADs,
those supported with LVADs will continue to have an
advantage in organ allocation that is not proportional to the
risk of adverse outcomes while listed for transplant. As the
number of registrants waiting with LVADs increases and
LVAD survival improves (survival with the HeartMate II
device is reported as 85% at 12 months) (8), the overall
efficacy of the transplant system, defined as maximizing
survival by provision of transplant according to risk while
waiting and following transplant, may decrease (8,9).
Study limitations. Although the differences in risk we
report point toward significant inequities on the transplant
list, the timing of listing and reasons for assigned urgency
must be carefully considered. We were not able to ade-
quately measure the differential risks between left-sided
paracorporeal support and right-sided or biventricular sup-
port due to insufficient data. From the limited sample of
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paracorporeal support may be lower risk than either biven-
tricular (regardless of whether one device is an implanted
LVAD) or right-sided paracorporeal support, although no
statistical difference was evident (p  0.46). Competition
within OPOs between LVAD-supported and other types of
registrants is rare on the basis of our analysis, although we
cannot account for body size restrictions or allosensitization
patterns, which would only reduce the number of registrants
appearing to compete for the same organ.
Conclusions
The historic allowance of 30 days of elective status 1A time
for implanted LVADs without complication no longer
promotes equality within the OPTN 1A urgency status.
Registrants with paracorporeal devices remain at high risk
for adverse events, and allowing indefinite status 1A time
for these registrants while reducing the allowance for stable
implanted LVADs would promote equalization of risk among
status 1A registrants. The popular idea that LVADs are not a
bridge but a necessary gateway to transplant should be treated
with caution to avoid over-application of LVAD therapy and
policies that create inequality on the transplant list.
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